Pericarditis clinical trials at UCSD
3 in progress, 2 open to eligible people
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
open to eligible people ages 18 years and up
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.
La Jolla, California and other locations
VTX2735 in Recurrent Pericarditis
open to eligible people ages 18-75
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A - A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A - An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B - A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C - An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C - A 14-day Follow-Up Period Cohort C will include approximately 20 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B - An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B - A 14-day Follow-Up Period
La Jolla, California and other locations
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Sorry, in progress, not accepting new patients
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
La Jolla, California and other locations
Our lead scientists for Pericarditis research studies include Ajit Raisinghani.
Last updated: